TIGER CHINA BIOTECH SOLACTIVE (371470) holdings & weights
Per-holding contribution · concentration · sector skew — a deep read
Fund overview
This is a Korea-listed ETF from 미래에셋자산운용. It tracks the Solactive China Biotech Index(PR). Key facts — expense ratio 0.49%; net assets about KRW 41.1B; inception 2020-12-08. Its 1-year return is -11.49%.
Fund details
Fund overview
This is a Korea-listed ETF from 미래에셋자산운용. It tracks the Solactive China Biotech Index(PR). Key facts — expense ratio 0.49%; net assets about KRW 41.1B; inception 2020-12-08. Its 1-year return is -11.49%.
30 identified stocks · net exposure / NAV 99.44%. Display weights are normalized to 100%; calculations retain original exposures without an additional leverage multiplier. Cash and unallocated contracts are excluded from stock attribution.
Weight and calculation basis
30 identified stocks · net exposure / NAV 99.44%. Display weights are normalized to 100%; calculations retain original exposures without an additional leverage multiplier. Cash and unallocated contracts are excluded from stock attribution.
Investor net buying
Latest-session net buying by foreigners, institutions and retail (positive = net buy, negative = net sell).
| Date | Change | Foreign | Inst. | Retail |
|---|---|---|---|---|
| 10/20 | +1.61% | −1.1K sh | +872 sh | +645 sh |
| 10/19 | -0.32% | +59 sh | −1.0K sh | +961 sh |
| 10/16 | -0.45% | −1.2K sh | +3.2K sh | +1.7K sh |
| 10/15 | -0.7% | +2.8K sh | +3.3K sh | −8.9K sh |
| 10/14 | -2.3% | −627 sh | +208 sh | +906 sh |
Investor flows
Investor net buying
Latest-session net buying by foreigners, institutions and retail (positive = net buy, negative = net sell).
| Date | Change | Foreign | Inst. | Retail |
|---|---|---|---|---|
| 10/20 | +1.61% | −1.1K sh | +872 sh | +645 sh |
| 10/19 | -0.32% | +59 sh | −1.0K sh | +961 sh |
| 10/16 | -0.45% | −1.2K sh | +3.2K sh | +1.7K sh |
| 10/15 | -0.7% | +2.8K sh | +3.3K sh | −8.9K sh |
| 10/14 | -2.3% | −627 sh | +208 sh | +906 sh |
We have this ETF's holdings, but the prices for those particular listings are outside our quote coverage (currently Korea- and US-listed securities). So today's contribution and return are not computed — showing 0% would claim it did not move, which is a different statement. The holdings and weights below follow the calculation basis above.
Today's summary
Its top 10 holdings make up about 69.3% of the fund. The concentration index (HHI) is 632 — Low — evenly diversified, and the largest sector is Unclassified (100%). The higher the concentration, the more one stock or sector drives the whole ETF's return.
Structural health
A five-axis read on how this fund is built. It is not a return forecast or a recommendation, and a low score does not mean a bad fund — leveraged products score low by design. Each axis shows the figure behind it.
Concentration is below 1,500 (632), so no single holding dominates.
Unclassified alone is 100%. This is effectively a bet on that one industry — if the sector falls, diversification will not help.
0.49% a year is typical. Held ten years, roughly 4.9% goes to fees.
Net assets of KRW 41.1B are small. Thin funds trade at wider spreads, and very small ones get closed or merged.
A plain 1x physical fund holding the shares themselves — no structural drift from how long you hold it.
Concentration and diversification
Structural health
A five-axis read on how this fund is built. It is not a return forecast or a recommendation, and a low score does not mean a bad fund — leveraged products score low by design. Each axis shows the figure behind it.
Concentration is below 1,500 (632), so no single holding dominates.
Unclassified alone is 100%. This is effectively a bet on that one industry — if the sector falls, diversification will not help.
0.49% a year is typical. Held ten years, roughly 4.9% goes to fees.
Net assets of KRW 41.1B are small. Thin funds trade at wider spreads, and very small ones get closed or merged.
A plain 1x physical fund holding the shares themselves — no structural drift from how long you hold it.
Top 20 holdings
3 derivative positions are excluded. Stock contributions do not explain the entire ETF return.
Weights are normalized to 100% of absolute exposures across analysed positions, including positions outside this top list. Cash, collateral and unverified assets are excluded. Contributions retain original signed NAV exposures; leverage is not applied twice.
Normalized to 100% of analysed positions
Weights are normalized to 100% of absolute exposures across analysed positions, including positions outside this top list. Cash, collateral and unverified assets are excluded. Contributions retain original signed NAV exposures; leverage is not applied twice.
| # | Holding | Weight |
|---|---|---|
| 1 | Wuxi Biologics Cayman2269 HK EQUITY | 11.23% |
| 2 | BeOne MedicinesBGNE | 10.93% |
| 3 | WuXi AppTec603259 C1 EQUITY | 10.49% |
| 4 | Innovent Biologics1801 HK EQUITY | 8.78% |
| 5 | Jiangsu Hengrui Pharmaceuticals600276 C1 EQUITY | 7.50% |
| 6 | Akeso9926 HK EQUITY | 5.93% |
| 7 | Sino Biopharmaceutical1177 HK EQUITY | 4.40% |
| 8 | Hansoh Pharmaceutical3692 HK EQUITY | 3.75% |
| 9 | Genscript Biotech1548 HK EQUITY | 3.45% |
| 10 | Pharmaron Beijing300759 C2 EQUITY | 2.87% |
| 11 | Shanghai RAAS Blood Products002252 C2 EQUITY | 2.67% |
| 12 | 3SBio1530 HK EQUITY | 2.65% |
| 13 | Sichuan Kelun-Biotech Biopharmaceutical6990 HK EQUITY | 2.37% |
| 14 | Gan & Lee Pharmaceuticals603087 C1 EQUITY | 2.29% |
| 15 | Hangzhou Tigermed Consulting300347 C2 EQUITY | 2.23% |
| 16 | Remegen688331 C1 EQUITY | 1.69% |
| 17 | Shanghai Allist Pharmaceuticals688578 C1 EQUITY | 1.69% |
| 18 | Sichuan Biokin Pharmaceutical688506 C1 EQUITY | 1.58% |
| 19 | Suzhou Zelgen Biopharmaceutical688266 C1 EQUITY | 1.51% |
| 20 | Shanghai Junshi Biosciences688180 C1 EQUITY | 1.42% |
Holdings below 0.5% or outside the top list are folded into “Others” and omitted above.
Where the weight sits — sector mix
Listed equity weights summed by sector and normalized to 100%. Each band is one sector's share.
HHI sums the squared weights. The more it leans on a few names, the higher it goes — and the more the whole ETF moves with them.
How concentrated is it
Concentration (HHI) is low at 632, with the top 10 holdings at just 69.3% of equity weight. No single name can dominate the fund.
Good for damping single-stock risk — and equally, a big winner inside gets diluted.
HHI squares each weight and sums them: 10,000 means one stock is everything, and the more evenly spread the holdings, the closer it falls to zero.
Where the sector weight sits
By sector, Unclassified alone is 100% — whatever the fund is called, this is a bet on that industry.
Bad news for the sector moves the whole fund. Worth checking against anything else you hold in the same space.
Weights above sum the individually listed equities and normalize that equity total to 100%.
How much it overlaps others
Even its closest peer, 499660, overlaps only 6% (1 shared names).
Funds filed under the same label can hold quite different companies, so pairing this one with another may genuinely spread risk.
What it is made of
The fund holds 34 positions in total; this page lists the largest 30 and folds the rest into "Others".
The expense ratio is 0.49% a year. Funds tracking the same index tend to perform alike, which makes the fee one of the few things that reliably separates them over time.
This page is not investment advice. Investment decisions and responsibility are your own.
371470 comments
Leave a one-line take on TIGER 차이나바이오테크SOLACTIVE. No account — just a nickname and a code to delete it later.
Loading…
Similar ETFs
Picked by how much their actual holdings overlap. The higher the overlap, the less diversification you get from owning both.